Skip to content
Mom holding baby

Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and NeoNatal Alloimmune Thrombocytopenia

Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects.

RallyBio News

RallyBio goes public.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common stock, at a public offering price of $13.00 per share.

Back To Top
Search